The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Novo Nordisk seeks to put a stop to semaglutide compounding, whereas the FDA agrees to allow compounding of tirzepatide, for ...

THE family of a dad who died suddenly believe a weight loss jab he used for just 19 days is to blame. Tim Ramsay, from South ...

“Although all dosages of a drug may currently be listed as available, the criteria for moving a drug ... The end of the ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro ... fasting ...

While the cost of medication isn’t included in the monthly plan cost, tirzepatide is available for about $130 per month with insurance, making it the most affordable option for individuals with ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...